These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 3248209)

  • 1. Profiles of non-compliance with antituberculous therapy.
    Wardman AG; Knox AJ; Muers MF; Page RL
    Br J Dis Chest; 1988 Jul; 82(3):285-9. PubMed ID: 3248209
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Low level of compliance with tuberculosis treatment in children: monitoring by urine tests.
    Palanduz A; Gültekin D; Erdem E; Kayaalp N
    Ann Trop Paediatr; 2003 Mar; 23(1):47-50. PubMed ID: 12648324
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Non-compliance with antituberculous drugs.
    Arnold AG; Curzon PG; Page RL; Williams SE
    Br J Dis Chest; 1984 Jul; 78(3):295-8. PubMed ID: 6743528
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An enquiry into the attitudes of South Indian patients to the coloration of their urine by rifampicin.
    Fox W; Prabhakar R; Ganapathy S; Somasundaram PR
    Tubercle; 1987 Sep; 68(3):201-7. PubMed ID: 3448796
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Attendance versus compliance with tuberculosis treatment in an occupational setting--a pilot study.
    Mqoqi NP; Churchyard GA; Kleinschmidt I; Williams B
    S Afr Med J; 1997 Nov; 87(11):1517-21. PubMed ID: 9472274
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Monitoring regularity of drug intake in tuberculous patients by means of simple urine tests.
    Burkhardt KR; Nel EE
    S Afr Med J; 1980 Jun; 57(24):981-5. PubMed ID: 7404075
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [The pharmacokinetics of rifampicin in the intermittent treatment of patients with pulmonary tuberculosis. 1. Excretion of rifampicin in the urine].
    Winsel K; Eule H; Werner E; Iwainsky H
    Pharmazie; 1985 Apr; 40(4):253-6. PubMed ID: 4011658
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Compliance with chemotherapy for tuberculosis.
    Corcoran R
    Ir Med J; 1986 Apr; 79(4):87-90. PubMed ID: 3710760
    [No Abstract]   [Full Text] [Related]  

  • 9. [Excretion of rifampin with urine during treatment of patients with tuberculosis].
    Ioffe RA
    Probl Tuberk; 1973; 51(12):43-6. PubMed ID: 4782103
    [No Abstract]   [Full Text] [Related]  

  • 10. [Qualitative reaction for determining rifampicin in the urine for the purpose of controlling patient intake of this preparation].
    Tatarinova NV; Zhuk NA; Chukanov VI
    Probl Tuberk; 1979 Aug; (8):62-5. PubMed ID: 482271
    [No Abstract]   [Full Text] [Related]  

  • 11. [Biotransformation of rifampicin in pulmonary tuberculosis patients].
    Ioffe RA
    Antibiotiki; 1977; 22(2):177-80. PubMed ID: 558736
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Short-term therapy of lung tuberculosis using a fixed combination of isoniazid, rifampicin and pyrazinamide. Results after 2 years].
    Brändli O; Haegi V; Villiger B; Bohn W; Baumann HR; Zäch R
    Schweiz Med Wochenschr; 1989 Mar; 119(10):299-305. PubMed ID: 2652281
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Short course chemotherapy for pulmonary tuberculosis.
    Ormerod LP; McCarthy OR; Rudd RM; Horsfield N
    Respir Med; 1991 Jul; 85(4):291-4. PubMed ID: 1947365
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The value of urine testing for verifying adherence to anti-tuberculosis chemotherapy in children and adults in Uganda.
    Meissner PE; Musoke P; Okwera A; Bunn JE; Coulter JB
    Int J Tuberc Lung Dis; 2002 Oct; 6(10):903-8. PubMed ID: 12365577
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of daily and twice-weekly regimens to treat pulmonary tuberculosis.
    Castelo A; Jardim JR; Goihman S; Kalckman AS; Dalboni MA; da Silva EA; Haynes RB
    Lancet; 1989 Nov; 2(8673):1173-6. PubMed ID: 2572899
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Risk factors for relapse in human immunodeficiency virus type 1 infected adults with pulmonary tuberculosis.
    Johnson JL; Okwera A; Vjecha MJ; Byekwaso F; Nakibali J; Nyole S; Milberg J; Aisu T; Whalen CC; Mugerwa RD; Ellner JJ
    Int J Tuberc Lung Dis; 1997 Oct; 1(5):446-53. PubMed ID: 9441100
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enhancement of treatment completion for latent tuberculosis infection with 4 months of rifampin.
    Lardizabal A; Passannante M; Kojakali F; Hayden C; Reichman LB
    Chest; 2006 Dec; 130(6):1712-7. PubMed ID: 17166986
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Clinical effects of rifampicin for pulmonary tuberculosis patients. 2. Results of rifampicin treatment for advanced pulmonary tuberculosis patients resistant to conventional antituberculous drugs].
    Kekkaku; 1971 Nov; 46(11):423-8. PubMed ID: 4335256
    [No Abstract]   [Full Text] [Related]  

  • 19. Treatment of isoniazid-resistant tuberculosis with isoniazid, rifampin, ethambutol, and pyrazinamide for 6 months.
    Nolan CM; Goldberg SV
    Int J Tuberc Lung Dis; 2002 Nov; 6(11):952-8. PubMed ID: 12475140
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Clinical evaluation of Rifampicin in pulmonary tuberculosis. 1. A preliminary study. The results of Rifampicin treatment for advanced pulmonary tuberculosis resistant to conventional antituberculous drugs].
    Donomae I; Fujita S; Gomi J; Hibino S; Horai Z
    Kekkaku; 1970 Aug; 45(8):251-6. PubMed ID: 5460317
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.